Two-stage hepatectomy after autologous CD133+ stem cells administration: a case report.
Liver resection is the mainstay of treatment for patients with primary and metastatic liver tumors. However, a large majority of patients present for initial medical evaluation with primary and metastatic liver tumors when their cancer is unresectable. Several trials have been undertaken to identify alternative treatments and complementary therapies. In the near future, the field of liver surgery will aim to increase the number of patients that can benefit from resection, since radical removal of the tumor currently provides the sole chance of cure. This paper reports the case of a patient with an advanced colonic cancer in the era of stem cell therapy. In 2011, a 57 years old white Caucasian man with a previous history of non-Hodgkin lymphoma (NHL) was diagnosed with colon cancer and bilobar liver metastases. Following neoadjuvant therapy, the patient was enrolled in a protocol of stem cell administration for liver regeneration. Surgery was initially performed on the primary cancer and left liver lobe. An extended right lobectomy to S1 was then performed after a portal vein embolization (PVE) and stem cell stimulation of the remaining liver. The postoperative course was uneventful and the patient was free of disease after 12 months. Extreme liver resection can provide a safer option and a chance of cure to otherwise unresectable patients when liver regeneration is boosted by PVE and stem cell administration.
Fondazione IRCCS Policlinico San Matteo, and University of Pavia, Viale Camillo Golgi 19, Pavia 27100PV, Italy.
Eloisa
E
Franchi
Maria C
MC
Canepa
Andrea
A
Peloso
Letizia
L
Barbieri
Laura
L
Briani
Gabor
G
Panyor
Paolo
P
Dionigi
Marcello
M
Maestri
D000071916:AC133 Antigen; D015703:Antigens, CD / Q000378:metabolism*; D003110:Colonic Neoplasms / Q000556:secondary / Q000601:surgery* / Q000628:therapy; D003131:Combined Modality Therapy; D006023:Glycoproteins / Q000378:metabolism*; D006498:Hepatectomy; D006801:Humans; D008113:Liver Neoplasms / Q000556:secondary / Q000601:surgery* / Q000628:therapy; D008115:Liver Regeneration; D008228:Lymphoma, Non-Hodgkin / Q000473:pathology / Q000601:surgery* / Q000628:therapy; D008297:Male; D008875:Middle Aged; D020360:Neoadjuvant Therapy; D010455:Peptides / Q000378:metabolism*; D011379:Prognosis; D033581:Stem Cell Transplantation; D014057:Tomography, X-Ray Computed
D000071916:AC133 Antigen; D015703:Antigens, CD; D006023:Glycoproteins; C000606023:PROM1 protein, human; D010455:Peptides